Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed client-serving-capacity dealings on 10 September 2026. It purchased 1,501,384 ordinary shares at 280.75p-281.75p and sold 643,838 shares at 280.75p-281.25p, for a net purchase of 857,546 shares. The Rule 8.5 filing reported no derivative transactions or other dealing arrangements.

Analysis

This is not informed insider accumulation: exempt-principal-trader activity by a mandated broker is ordinarily client facilitation, market-making, or residual inventory management. The net share balance is therefore not a reliable indicator of either deal certainty or the adviser’s proprietary view, and should not be extrapolated into a directional signal for INVP or Advanced Medical Solutions (AMS.L).

The relevant trading signal is liquidity, not ownership. Concentrated two-way broker flow near a narrow price band can temporarily stabilize the target’s trading level, but that support may disappear quickly if client demand fades; this raises gap risk for a relatively less-liquid UK small/mid-cap target if the transaction timeline changes. Over the next 1-3 months, the material drivers remain formal offer terms, financing certainty, regulatory conditions, and any competing-bid probability—not subsequent Rule 8.5 forms.

For INVP, advisory economics from a single UK mid-cap mandate are immaterial to earnings and should not affect valuation. The more useful read-through is whether a completed transaction reinforces Investec’s UK corporate-finance pipeline and fee-wallet share, which would only become investable if accompanied by evidence of broader mandate conversion or upgraded segment guidance over the next 6-18 months.

Contrarian view: takeover-related disclosures often attract retail interpretation as "smart-money buying," creating an avoidable premium in the target. Unless the spread to confirmed consideration is unusually wide after adjusting for closing probability and time-to-close, there is no statistical edge in following intermediary dealing; the asymmetry is generally negative because downside on a deal break exceeds residual upside to terms.

Key Decisions for Investors

• No directional trade based on this filing. Treat further Rule 8.5 disclosures in AMS.L as non-informative unless they coincide with a disclosed change in offer consideration, financing, or a Rule 8.3 beneficial-owner position.
• For existing AMS.L merger-arbitrage exposure, size to deal-break downside rather than apparent broker demand; reassess immediately if the market price moves more than 3-5% away from confirmed consideration or if the expected closing date slips by more than one quarter.
• Do not use INVP as a proxy long for this event. Revisit only after results quantify advisory-fee growth, pipeline conversion, or capital-return capacity; a mandate-related fee contribution alone is unlikely to move consensus EPS.
• Set an alert for a revised proposal, a competing bidder, or regulatory/financing disclosures. A credible competing bid is the only near-term catalyst that could justify owning AMS.L above a conventional cash-deal spread valuation; absence of such evidence favors reducing any premium-to-terms exposure.